glp 1 drugs and blindness A nurse lost her eyesight while on GLP-1 drugs. She said she did not know of the potential risk, which is listed on the packaging in Europe but not in the U.S Glucagon-like peptide-1 medicines in neurological

Together, these developments underscore the dynamic interplay between medical advances, social attitudes, and the lived experiences of individuals with obesity, highlighting the need for continued dialog around the ethical, cultural, and clinical implications of obesity treatment

New Trends Clin Neuropharmacol 1989;3(2):131-132

Neklesa, T

This episode should be of interest to listeners curious about maximizing their vitality and longevity and to anyone seeking science-supported ways to improve mental health and lifespan

Duration: 2-4 weeks intensive phase, followed by 4-8 weeks standard protocol

Physiological experiments in human volunteers revealed different increments in insulin secretion after oral and intravenous glucose administration, which were subsequently attributed to the actions of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [1]